| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 85027 |
|
702 |
698 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
1,082 |
1,052 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
288 |
281 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,411 |
1,401 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
302 |
300 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
200 |
198 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
299 |
293 |
$0.00 |
| 3044F |
|
160 |
160 |
$0.00 |
| 86593 |
|
245 |
244 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
526 |
504 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
325 |
324 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
2,745 |
2,538 |
$0.00 |
| 3079F |
|
109 |
101 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
511 |
504 |
$0.00 |
| 1111F |
|
155 |
135 |
$0.00 |
| 3074F |
|
387 |
347 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
210 |
205 |
$0.00 |
| 82043 |
|
139 |
138 |
$0.00 |
| 3075F |
|
92 |
89 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
13 |
12 |
$0.00 |
| 99386 |
|
12 |
12 |
$0.00 |
| 99443 |
|
26 |
25 |
$0.00 |
| 4450F |
|
15 |
15 |
$0.00 |
| 81001 |
|
12 |
12 |
$0.00 |
| 86780 |
|
53 |
52 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
12 |
12 |
$0.00 |
| 1220F |
|
15 |
15 |
$0.00 |
| 90686 |
|
13 |
13 |
$0.00 |
| 90656 |
|
13 |
13 |
$0.00 |
| 86592 |
|
15 |
15 |
$0.00 |
| 86703 |
|
551 |
547 |
$0.00 |
| 80061 |
Lipid panel |
1,126 |
1,123 |
$0.00 |
| 3077F |
|
114 |
106 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,470 |
1,250 |
$0.00 |
| 3078F |
|
453 |
396 |
$0.00 |
| 82540 |
|
139 |
138 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
200 |
198 |
$0.00 |
| 84450 |
|
46 |
46 |
$0.00 |
| 99442 |
|
51 |
51 |
$0.00 |
| 84460 |
|
12 |
12 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$0.00 |
| 82274 |
|
26 |
26 |
$0.00 |